mRNA Synthesis Raw Materials Market Size & Growth Forecast 2027–2036, By Segments (Application, End-use, Type), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
mRNA Synthesis Raw Materials Market size stood at USD 1.8 billion in 2026 and is predicted to grow at a 6.75% CAGR from 2027 to 2036, exceeding USD 3.46 billion by 2036. The industry revenue for 2027 is estimated at USD 1.9 billion.
Get more details on this report
Request Free Sample ReportmRNA Synthesis Raw Materials Market Intelligence Snapshot
Regional Market Dynamics
- North America accounted for 38.16% of the market in 2026, supported by advanced biopharmaceutical manufacturing, integrated supplier networks, and strong demand from clinical and commercial mRNA programs.
- Asia Pacific is projected to expand at a 3.31% CAGR as biomanufacturing capacity grows, biotechnology infrastructure improves, and organizations increase mRNA development and production activities.
Segment Momentum
- Vaccine Production accounted for a 79.76% share in 2026, driven by large-scale manufacturing, standardized sourcing practices, recurring procurement, and stringent quality requirements for high-purity raw materials.
- CROs & CMOs are expanding fastest as more developers outsource mRNA development and manufacturing to gain technical expertise, flexibility, and production capacity without significant in-house infrastructure investment.
Market Expansion Drivers
- Expanding mRNA vaccine and therapeutic pipeline driving reagent consumption growth.
- GMP-compliant biomanufacturing expansion increasing demand for high-purity synthesis materials.
- Supply chain localization efforts strengthening regional sourcing of critical biopharma raw materials.
Leading Market Participants
- Leading players in the mRNA synthesis raw materials market include Merck KGaA (Germany), Thermo Fisher Scientific Inc. (United States), F. Hoffmann-La Roche Ltd. (Switzerland), Maravai LifeSciences Holdings, Inc. (United States), New England Biolabs, Inc. (United States), Jena Bioscience GmbH (Germany), Hongene Biotech Corporation (China), Yeasen Biotechnology (Shanghai) Co., Ltd. (China), Danaher Corporation (United States), TriLink BioTechnologies LLC (United States).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 1.8 billion
- 2027 Estimated Market Size: USD 1.9 billion.
- Projected Market Size: USD 3.46 billion by 2036
- Growth Forecast: 6.75% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Vaccine Production (Application) | Biopharmaceutical & Pharmaceutical Companies (End-use) | Nucleotides (Type)
- Emerging Opportunity Segment: Therapeutics Production (Application) | CROs & CMOs (End-use) | Capping Agents (Type)
Market Growth Drivers and Industry Trends
Expanding mRNA vaccine and therapeutic pipeline driving reagent consumption growth
The expansion of mRNA-based vaccine and therapeutic development programs is increasing demand for the specialized reagents and materials required throughout mRNA synthesis and formulation workflows. This pipeline expansion will drive the mRNA synthesis raw materials market growth as research and manufacturing activities require consistent supplies of nucleotides, enzymes, capping components, and other synthesis-related materials. The broader exploration of mRNA technology across infectious disease, oncology, and other therapeutic applications is increasing the number of development programs requiring scalable and reliable raw material inputs. As more candidates progress through development stages, the need for specialized synthesis materials is expanding across research and biomanufacturing environments.
GMP-compliant biomanufacturing expansion increasing demand for high-purity synthesis materials
The expansion of good manufacturing practice-compliant biomanufacturing capacity is increasing requirements for raw materials that meet stringent standards for purity, consistency, traceability, and quality control. This development will propel the mRNA synthesis raw materials market growth as manufacturers require high-quality inputs suitable for regulated production environments and clinical or commercial manufacturing workflows. GMP-compliant materials help support reproducible synthesis processes and reduce risks associated with impurities or variability in critical production inputs. The increasing transition of mRNA technologies from research settings toward larger-scale therapeutic manufacturing is strengthening demand for qualified and consistently produced synthesis materials.
Supply chain localization efforts strengthening regional sourcing of critical biopharma raw materials
Biopharmaceutical manufacturers are increasingly seeking to strengthen regional supply networks and reduce dependence on concentrated sources for critical production inputs. These localization efforts will boost the mRNA synthesis raw materials market demand by encouraging the development of regional suppliers and sourcing capabilities for essential materials used in mRNA manufacturing. Greater geographic diversification can help manufacturers improve supply continuity, manage procurement risks, and respond more effectively to disruptions affecting international logistics or specialized raw material availability. The emphasis on resilient biopharmaceutical supply chains is also encouraging closer coordination between raw material producers and regional manufacturing ecosystems.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Expanding mRNA vaccine and therapeutic pipeline driving reagent consumption growth | 2.60% | High | North America, Europe | High | Mid Term |
| GMP-compliant biomanufacturing expansion increasing demand for high-purity synthesis materials | 2.30% | High | North America, Asia Pacific, Europe | High | Mid Term |
| Supply chain localization efforts strengthening regional sourcing of critical biopharma raw materials | 1.70% | Moderate | North America, Europe, Asia Pacific | Medium | Long Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
In the mRNA synthesis raw materials market, North America held the largest share of 38.16% in 2026, reflecting its strong biotechnology ecosystem, advanced biopharmaceutical manufacturing capabilities, and substantial research activity involving mRNA-based technologies. The region benefits from sophisticated laboratory infrastructure and established capabilities for producing and handling specialized materials required for mRNA development. Continued innovation in nucleic acid therapeutics, expansion of biomanufacturing capacity, and increasing demand for high-quality raw materials are supporting regional market leadership.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is projected to be the fastest-growing region as pharmaceutical and biotechnology industries expand their capabilities in advanced therapeutics and nucleic acid technologies. Increasing investment in biopharmaceutical research, improvements in manufacturing infrastructure, and growing efforts to strengthen domestic production capabilities are creating additional demand for mRNA synthesis inputs. The broader development of biotechnology ecosystems and rising interest in innovative therapeutic platforms are expected to further accelerate regional adoption.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Quality Manufacturing BaseGermany emphasizes high-purity raw materials that support regulated mRNA manufacturing and pharmaceutical innovation. Suppliers focus on scalable production, stringent quality control, and close collaboration with biotechnology companies developing next-generation RNA-based therapies.
France 🇫🇷
Research Collaboration FocusFrance supports the mRNA synthesis raw materials market through collaborative pharmaceutical research and biotechnology development initiatives. Material suppliers increasingly provide specialized reagents and technical support that improve manufacturing efficiency and product consistency.
Italy 🇮🇹
Specialized Reagent SupplyItaly strengthens the mRNA synthesis raw materials market by expanding access to specialized laboratory reagents and pharmaceutical manufacturing inputs. Companies increasingly seek dependable suppliers capable of supporting flexible production requirements and regulatory compliance.
Japan 🇯🇵
Precision Material StandardsJapan prioritizes reliable and highly consistent raw materials for mRNA synthesis across research and clinical applications. Domestic demand encourages suppliers to enhance manufacturing precision, analytical validation, and long-term supply continuity for pharmaceutical developers.
South Korea 🇰🇷
Biotech Capacity SupportSouth Korea is expanding demand for mRNA synthesis raw materials through investments in biotechnology manufacturing and contract development services. Suppliers increasingly align production capabilities with scalable RNA platforms and internationally accepted quality requirements.
United States 🇺🇸
Bioprocess Supply ExpansionThe U.S. mRNA synthesis raw materials market is driven by continued investment in biopharmaceutical manufacturing and advanced therapeutics. Companies prioritize secure sourcing of nucleotides, enzymes, and specialized reagents while strengthening domestic supply resilience for research and commercial production.
Segment Leadership and Growth Trends
mRNA Synthesis Raw Materials Market Share (%), by Application, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportApplication Segment Analysis: Vaccine Production (Largest Segment) vs Therapeutics Production (Fastest-Growing Segment)
Vaccine production dominated the mRNA synthesis raw materials market, accounting for 79.76% share in 2026, reflecting the substantial requirement for specialized raw materials throughout mRNA-based vaccine manufacturing. Reliable availability of nucleotides, enzymes, capping components, and other synthesis inputs is essential for producing consistent and high-quality mRNA constructs. Continued interest in mRNA-based vaccine platforms and the need for scalable, reproducible manufacturing processes support sustained demand for synthesis raw materials within vaccine development and production activities.
Therapeutics production is the fastest-growing application segment as mRNA technology expands beyond preventive vaccination into broader therapeutic applications. mRNA-based approaches can support the development of treatments designed to produce specific proteins or influence biological pathways, creating demand for raw materials capable of meeting diverse synthesis and formulation requirements. Increasing research activity around therapeutic applications and the pursuit of flexible RNA-based treatment platforms are encouraging greater utilization of specialized synthesis inputs.
End-use Segment Analysis: Biopharmaceutical & Pharmaceutical Companies (Largest Segment) vs CROs & CMOs (Fastest-Growing Segment)
Biopharmaceutical & pharmaceutical companies held the largest share of the mRNA synthesis raw materials market, accounting for 52.18% in 2026, due to their direct involvement in the development, validation, and commercialization of mRNA-based products. These organizations require consistent access to high-quality synthesis inputs to support research programs, process development, and manufacturing activities. Growing investment in RNA-based platforms and the expansion of mRNA development pipelines are strengthening demand from established pharmaceutical and biopharmaceutical end users.
CROs & CMOs represent the fastest-growing end-use segment as mRNA developers increasingly rely on external partners for specialized research, development, testing, and manufacturing capabilities. Outsourcing can provide access to technical expertise, specialized production infrastructure, and flexible capacity without requiring organizations to build every capability internally. The increasing complexity of mRNA development and the need to accelerate development workflows are encouraging broader use of contract research and manufacturing services, thereby supporting demand for synthesis raw materials among CROs and CMOs.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Application | Vaccine Production, Therapeutics Production, Others | Vaccine Production | Therapeutics Production |
| End-use | Biopharmaceutical & Pharmaceutical Companies, CROs & CMOs, Academic & Research Institutes | Biopharmaceutical & Pharmaceutical Companies | CROs & CMOs |
| Type | Capping Agents, Nucleotides, Plasmid DNA, Enzymes, Others | Nucleotides | Capping Agents |
Competitive Landscape and Market Positioning
Key companies in the mRNA synthesis raw materials market:
1. Merck KGaA (Germany)
2. Thermo Fisher Scientific Inc. (United States)
3. F. Hoffmann-La Roche Ltd. (Switzerland)
4. Maravai LifeSciences Holdings Inc. (United States)
5. New England Biolabs Inc. (United States)
6. Jena Bioscience GmbH (Germany)
7. Hongene Biotech Corporation (China)
8. Yeasen Biotechnology (Shanghai) Co. Ltd. (China)
9. Danaher Corporation (United States)
10. TriLink BioTechnologies LLC (United States)
Rising biopharmaceutical innovation is driving strong momentum in the mRNA synthesis raw materials market. The mRNA synthesis raw materials market is evolving through advanced molecular techniques that enhance synthesis accuracy and scalability. Continuous research focus is enabling more stable and efficient raw material development for therapeutic applications.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Merck KGaA (Germany) | |||||||
| Thermo Fisher Scientific Inc. (United States) | |||||||
| F. Hoffmann-La Roche Ltd. (Switzerland) | |||||||
| Maravai LifeSciences Holdings Inc. (United States) | |||||||
| New England Biolabs Inc. (United States) | |||||||
| Jena Bioscience GmbH (Germany) | |||||||
| Hongene Biotech Corporation (China) | |||||||
| Yeasen Biotechnology (Shanghai) Co. Ltd. (China) | |||||||
| Danaher Corporation (United States) | |||||||
| TriLink BioTechnologies LLC (United States). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Moderna | Nov-25 | Moderna invested USD 140 million to complete its domestic mRNA manufacturing network in the United States. The investment strengthens local production capacity and increases demand for mRNA synthesis raw materials, reinforcing supply chain localization and supporting scalable mRNA therapeutic manufacturing infrastructure. |
| BioSpring | Jul-25 | BioSpring committed several hundred million euros to build a ton-scale RNA manufacturing facility in Germany. The investment significantly expands European RNA raw material production capacity and strengthens regional supply resilience for mRNA-based therapeutics and vaccines. |
| TriLink BioTechnologies | May-25 | TriLink BioTechnologies and the International Vaccine Institute signed an MoU to co-develop mRNA vaccines for global access. The collaboration supports expanded mRNA production initiatives and reinforces demand for synthesis raw materials within equitable vaccine development programs. |
| Syvento Biotech | Nov-24 | Syvento Biotech and Cytiva inaugurated a FlexFactory facility in Poland to accelerate mRNA therapy development. The modular, automated platform enhances manufacturing scalability and digital integration, strengthening regional capacity for mRNA production and supporting faster therapeutic development timelines. |
| Hongene Biotech Corporation | Sep-24 | Hongene Biotech Corporation and ReciBioPharm formed a strategic partnership integrating sgRNA synthesis technology into a unified gene editing manufacturing platform. The collaboration enables end-to-end capabilities including plasmid, mRNA, sgRNA, and LNP production, improving process integration and reducing manufacturing fragmentation. |
| GenScript | May-24 | GenScript launched a self-amplifying RNA synthesis service for therapeutic applications. The offering enhances production capabilities for vaccines and gene therapies, strengthening its position in the expanding RNA synthesis and advanced biologics manufacturing ecosystem. |
| Merck KGaA | Feb-22 | Merck KGaA acquired Exelead, a U.S.-based CDMO, to strengthen its mRNA vaccine and therapeutic development capabilities. The acquisition supports long-term expansion of lipid and mRNA manufacturing capacity and reinforces Merck’s position in advanced nucleic acid-based therapeutics. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
mRNA Synthesis Raw Materials Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Synthesis Stage | Template Preparation, In Vitro Transcription, RNA Capping & Polyadenylation, RNA Purification & Processing |
| Manufacturing Scale | Research & Laboratory Scale, Pilot & Clinical Scale, Commercial Manufacturing Scale |
| Supply Chain Model | Direct Manufacturer Supply, Distributor & Specialty Supplier Supply, Contract Manufacturing Supply |
mRNA Synthesis Raw Materials Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Raw Material Supply Security Assessment |
|
| mRNA Manufacturing Ecosystem Analysis |
|
| Next-Generation Material Innovation Trends |
|
Need a different cut of the data?
Request Custom ResearchWhat is the current size of the mRNA synthesis raw materials market?
How is the mRNA synthesis raw materials industry size expected to evolve during the forecast period?
How is the expanding mRNA vaccine and therapeutics pipeline reshaping procurement and consumption of synthesis raw materials?
How are GMP biomanufacturing requirements influencing supplier selection and material specifications in the mRNA synthesis raw materials market?
Why does Vaccine Production lead the mRNA synthesis raw materials market?
Why are CROs & CMOs the fastest-growing end users in the mRNA synthesis raw materials market?
Why is North America the leading market for mRNA synthesis raw materials?
Which region is expected to grow fastest in the mRNA synthesis raw materials market?
Who are the leading players in the mRNA synthesis raw materials landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization